Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Praxis Precision Medicines Inc (PRAX)

Praxis Precision Medicines Inc (PRAX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 7,993,111
  • Shares Outstanding, K 25,195
  • Annual Sales, $ 8,550 K
  • Annual Income, $ -182,820 K
  • EBIT $ -293 M
  • EBITDA $ -298 M
  • 60-Month Beta 2.85
  • Price/Sales 917.50
  • Price/Cash Flow N/A
  • Price/Book 19.55

Options Overview Details

View History
  • Implied Volatility 73.79% (+4.12%)
  • Historical Volatility 95.97%
  • IV Percentile 14%
  • IV Rank 3.48%
  • IV High 241.91% on 02/07/25
  • IV Low 67.73% on 10/22/25
  • Expected Move (DTE 30) 48.79 (15.05%)
  • Put/Call Vol Ratio 0.21
  • Today's Volume 86
  • Volume Avg (30-Day) 216
  • Put/Call OI Ratio 2.90
  • Today's Open Interest 8,000
  • Open Int (30-Day) 18,403
  • Expected Range 275.29 to 372.87

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 16 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -3.00
  • Number of Estimates 8
  • High Estimate -2.17
  • Low Estimate -3.45
  • Prior Year -2.94
  • Growth Rate Est. (year over year) -2.04%

Price Performance

See More
Period Period Low Period High Performance
1-Month
266.51 +21.60%
on 12/26/25
326.91 -0.87%
on 01/16/26
+51.16 (+18.75%)
since 12/19/25
3-Month
154.45 +109.83%
on 11/05/25
326.91 -0.87%
on 01/16/26
+149.01 (+85.11%)
since 10/20/25
52-Week
26.70 +1,113.78%
on 04/09/25
326.91 -0.87%
on 01/16/26
+253.54 (+359.43%)
since 01/17/25

Most Recent Stories

More News
Praxis Precision Medicines Appoints Global Epilepsy Leader Dr. Orrin Devinsky as Head of Clinical Strategy

BOSTON, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today...

PRAX : 324.08 (+2.15%)
Praxis Precision Medicines Enters Its Next Chapter Following a Pivotal Year of Progress

Two NDA submissions expected by mid-February 2026 for ulixacaltamide in essential tremor and relutrigine in SCN2A/8A-DEEs, both with Breakthrough Therapy Designation from the FDA Multiple registrational...

PRAX : 324.08 (+2.15%)
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for...

PRAX : 324.08 (+2.15%)
Praxis Precision Medicines Further Positioned for Next-Phase Growth with Key Board and Executive Appointments

BOSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for...

PRAX : 324.08 (+2.15%)
Praxis Precision Medicines, Inc. Announces Pricing of $575 Million Public Offering

BOSTON, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...

PRAX : 324.08 (+2.15%)
Praxis Precision Medicines, Inc. Announces Proposed Public Offering

BOSTON, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...

PRAX : 324.08 (+2.15%)
Stocks Settle Lower as Weakness in Big Tech Weighs

The S&P 500 Index ($SPX ) (SPY ) on Monday closed down -0.35%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed down -0.51%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -0.46%. March E-mini...

GOOGL : 322.00 (-2.42%)
AAPL : 246.70 (-3.46%)
HL : 28.24 (+6.41%)
CDE : 22.87 (+1.28%)
$IUXX : 24,987.57 (-2.12%)
ZNH26 : 111-165 (+0.08%)
MSFT : 454.52 (-1.16%)
OXY : 42.24 (-1.08%)
TSLA : 419.25 (-4.17%)
ESH26 : 6,853.50 (+0.35%)
FANG : 148.70 (-1.71%)
VLO : 184.73 (+0.69%)
Stocks Fall as Megacap Technology Stocks Slide and Metals Plunge

The S&P 500 Index ($SPX ) (SPY ) today is down -0.24%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.09%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.24%. March E-mini S&P futures...

GOOGL : 322.00 (-2.42%)
AAPL : 246.70 (-3.46%)
HL : 28.24 (+6.41%)
CVX : 165.30 (-0.58%)
CDE : 22.87 (+1.28%)
$IUXX : 24,987.57 (-2.12%)
ZNH26 : 111-165 (+0.08%)
MSFT : 454.52 (-1.16%)
OXY : 42.24 (-1.08%)
TSLA : 419.25 (-4.17%)
ESH26 : 6,853.50 (+0.35%)
FANG : 148.70 (-1.71%)
Stocks Slip Due to Weakness in Megacap Technology Stocks

The S&P 500 Index ($SPX ) (SPY ) today is down -0.24%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.09%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.24%. March E-mini S&P futures...

GOOGL : 322.00 (-2.42%)
MPC : 174.88 (-0.43%)
AAPL : 246.70 (-3.46%)
HL : 28.24 (+6.41%)
CVX : 165.30 (-0.58%)
CDE : 22.87 (+1.28%)
$IUXX : 24,987.57 (-2.12%)
ZNH26 : 111-165 (+0.08%)
MSFT : 454.52 (-1.16%)
OXY : 42.24 (-1.08%)
TSLA : 419.25 (-4.17%)
ESH26 : 6,853.50 (+0.35%)
Praxis Precision Medicines Announces the FDA Has Granted Breakthrough Therapy Designation for Ulixacaltamide HCl in Essential Tremor

The Breakthrough Therapy Designation was granted based on the positive topline results from the Essential3 Phase 3 program in essential tremor Praxis remains on track to submit ulixacaltamide NDA...

PRAX : 324.08 (+2.15%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Praxis Precision Medicines Inc. is a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders characterized by neuronal imbalance. Praxis Precision Medicines Inc. is based in CAMBRIDGE, Mass.

See More

Key Turning Points

3rd Resistance Point 349.89
2nd Resistance Point 337.97
1st Resistance Point 331.03
Last Price 324.08
1st Support Level 312.17
2nd Support Level 300.25
3rd Support Level 293.31

See More

52-Week High 326.91
Last Price 324.08
Fibonacci 61.8% 212.23
Fibonacci 50% 176.81
Fibonacci 38.2% 141.38
52-Week Low 26.70

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar